FDA May Grant Advantages For Vertex's Telaprevir Over Merck's Boceprevir
Heading into an Antiviral Products Advisory Committee review April 28, FDA briefing documents indicate some strengths for Vertex's HCV drug over Merck's boceprevir.
Heading into an Antiviral Products Advisory Committee review April 28, FDA briefing documents indicate some strengths for Vertex's HCV drug over Merck's boceprevir.